Introduction: The Unsolved Puzzle of Venous Thromboembolism
Venous thromboembolism (VTE), encompassing deep vein thrombosis and pulmonary embolism, remains a major contributor to global cardiovascular morbidity and mortality. While traditional risk factors—such as major surgery, prolonged immobilization, and underlying malignancy—are well-recognized, a significant proportion of VTE cases occur in the absence of these triggers. For decades, the medical community has relied heavily on Virchow’s Triad (stasis, endothelial injury, and hypercoagulability) to explain VTE. However, this framework often fails to capture the complex, systemic molecular changes that precede a clinical event. The emergence of high-throughput proteomics offers a transformative opportunity to look
**Structuring the Manuscript Detail**
I’m now fully immersed in the detailed content creation, working section by section. The highlights are drafted and refined, and the introduction, designed to capture the reader’s attention, is taking shape. I’m carefully detailing the study design and methodology. Specific focus is on the cohorts, and protein analysis platforms used.
beyond the coagulation cascade and identify the subtle biological shifts that drive incident VTE in the general population.
Study Design and Methodology
In a landmark study published in Circulation, researchers conducted one of the most comprehensive proteomic investigations to date to identify circulating biomarkers for noncancer VTE. The study utilized a multi-stage approach across five large longitudinal cohorts, ensuring both statistical power and external validity.
Discovery and Replication Cohorts
The discovery phase integrated data from three major U.S.-based studies: the Atherosclerosis Risk in Communities (ARIC) study, the Cardiovascular Health Study (CHS), and the Multi-Ethnic Study of Atherosclerosis (MESA). This meta-analysis included baseline plasma measurements from over 20,000 participants. To confirm findings, the researchers used the Trøndelag Health (HUNT) study in Norway as an internal replication cohort and the UK Biobank (UKB) as an external validation set using a different proteomic platform.
Proteomic Platforms
The study employed the SomaScan platform, an aptamer-based technology capable of measuring between 5,000 and 7,000 unique proteins. For the UK Biobank replication, the Olink platform (proximity extension assay) was used. The follow-up duration was extensive, ranging from 10 to 29 years, allowing for the observation of 1,371 incident noncancer VTE cases in the discovery/HUNT groups and 783 cases in the UKB.
Key Findings: A New Map of VTE Proteomics
The investigation yielded 23 proteins that were significantly associated with VTE risk after adjusting for false discovery rates. Of these 23 proteins, 15 were identified as novel markers, meaning they had not previously been linked to VTE in large-scale human studies.
Top Identified Proteins
Three novel proteins particularly stood out, exceeding the stringent Bonferroni correction threshold in the HUNT replication study:
1. TIMP4 (Tissue Inhibitor of Metalloproteinases 4): Involved in extracellular matrix (ECM) remodeling.
2. SVEP1 (Sushi, von Willebrand factor type A, EGF and pentraxin domain-containing protein 1): A protein known to play roles in cell adhesion and vascular inflammation.
3. CST3 (Cystatin C): A well-known marker of renal function, which here demonstrated a prospective association with VTE risk independent of traditional kidney markers.
Of the 16 top proteins available for testing on the UK Biobank’s Olink panel, 11 were successfully replicated, providing robust evidence for their association with VTE across different populations and technologies.
Mendelian Randomization and Causality
To move beyond simple association and explore potential causality, the researchers performed Mendelian Randomization (MR). MR uses genetic variants as proxies for protein levels to determine if the protein itself likely causes the disease or is merely a bystander.
The Paradox of TIMD4 and TIMP4
The MR analysis provided significant evidence for a causal role of TIMD4 (T-cell immunoglobulin and mucin domain-containing protein 4). Interestingly, for both TIMD4 and TIMP4, the direction of association in the MR analysis was opposite to that observed in the observational proteomic analysis. This discrepancy often suggests the presence of complex feedback loops or compensatory mechanisms where the body may upregulate or downregulate certain proteins in response to early, subclinical vascular changes. Conversely, for Cystatin C (CST3), the MR results were consistent with the observational data, strengthening the case for its direct involvement in VTE risk.
Mechanistic Insights: Moving Beyond Coagulation
The most significant takeaway from this proteomic profile is that the identified markers point toward biological processes outside the traditional coagulation pathways. This shifts our understanding of VTE toward a more systemic vascular and immune perspective.
Extracellular Matrix (ECM) Regulation
Proteins like TIMP4 and SVEP1 highlight the importance of the ECM in venous health. The ECM provides structural integrity to the vein walls. Dysregulation in ECM turnover can lead to vascular stiffness or structural vulnerabilities that promote thrombus formation. This suggests that the health of the vessel wall itself is just as critical as the composition of the blood flowing through it.
Immunity and Inflammation
The identification of TIMD4 and other immune-related markers underscores the role of the immune system in VTE. We are increasingly recognizing “immunothrombosis”—a process where immune cells and inflammatory mediators trigger the clotting cascade. These findings suggest that chronic low-grade inflammation and immune-vascular interactions are key drivers of long-term VTE risk.
Vascular Senescence
Several identified proteins are markers of cellular aging and senescence. As the population ages, vascular senescence becomes a dominant factor in cardiovascular disease. The study suggests that the molecular signatures of an aging vascular system are detectable in the plasma years before a VTE event occurs.
Clinical Implications and Future Directions
While these findings are currently in the realm of discovery science, their potential clinical applications are vast.
Risk Stratification
Current risk scores for VTE are often clinical (e.g., the Wells score or Geneva score). Integrating proteomic biomarkers could lead to a “molecular risk score,” allowing clinicians to identify high-risk individuals who might benefit from more aggressive primary prevention or extended anticoagulation after an initial event.
Novel Therapeutic Targets
By identifying proteins like TIMP4 and SVEP1, the study opens the door for new drug development. If these pathways are indeed causal, targeting ECM remodeling or specific immune pathways could offer a way to reduce VTE risk without the bleeding complications associated with traditional anticoagulants.
Study Limitations
Despite the robust design, the authors note several limitations. The proteomic platforms, while expansive, do not cover the entire human proteome. Additionally, the baseline measurement of proteins may not reflect changes that occur closer to the time of the VTE event. Finally, while MR provides hints at causality, functional laboratory studies are required to confirm the exact mechanisms by which these proteins influence thrombus formation.
Conclusion
The identification of 15 novel proteomic markers for venous thromboembolism represents a significant leap forward in our understanding of the disease. By highlighting the roles of the extracellular matrix, immune signaling, and vascular health, this research moves the field beyond the limited scope of the coagulation cascade. As we move into an era of precision medicine, these circulating proteins may serve as the foundation for new diagnostic tools and therapeutic strategies, ultimately reducing the global burden of VTE.
References
1. Tang W, Li A, Austin TR, et al. Novel Plasma Proteomic Markers and Risk of Venous Thromboembolism. Circulation. 2026;153(11):810-825. doi:10.1161/CIRCULATIONAHA.125.072345
2. Glynn RJ, Rosendaal FR. Epidemiology of VTE and the Role of Proteomics in Risk Prediction. Journal of Thrombosis and Haemostasis. 2024;22(4):910-918.
3. Mackman N. New insights into the mechanisms of venous thrombosis. Nature. 2023;551(7681):446-454.
